

## Reduce the Level of Host Cell Proteins in the Bioreactor Harvest

Host cell proteins (HCPs) are an inevitable byproduct of biologics manufacturing and can have an impact on product quality and efficacy as well as patient safety. Processes designed to remove HCPs from the bioreactor harvest must not only be successful in achieving acceptable limits, but also be scalable.

The combination of our innovative, custom solutions and decades of expertise in biologics manufacturing allows us conceptualize and implement effective approaches to address process development challenges such as HCP removal, in an accelerated timeframe.



### The Challenge

Our customer had one month to reduce the level of HCPs in the bioreactor harvest prior to a production run to supply drug substance for a scheduled Phase 1 clinical trial. The high level of HCPs (1,000,000 in the harvest and 700 ppm at the end of purification) unfavorably impacted the planned clarification process and subsequent downstream steps. The goal was to reduce the level of HCPs to maximum of 300 ppm at the end of process purification and ensure clarification of the entire 2000L harvest.



### Our Approach

HCP levels can be reduced using mixed-mode and hydrophobic interaction columns, but these approaches are more complex and would not have allowed us to deliver an optimized solution within the compressed timeframe. Further, these options would not solve the problem of clarification filter filterability of the 2000L. A reduction in bioreactor size to 1000L, which would allow for clarification, was not feasible due to the amount of drug substance needed for the trial. The approach selected to drastically reduce HCPs and increase filterability was caprylic acid precipitation followed by filtration using Clarisolve® filters. Design of experiments (DOE) was used to identify the optimal conditions for precipitation with a focus on two key parameters, the concentration of caprylic acid and temperature. Use of DOE enabled us to reduce the number of experiments required to evaluate these parameters, which was crucial as we had a limited number of time and cells available for the study.



### The Outcome

The combination of caprylic acid precipitation and Clarisolve® filters enabled a reduction of 80% of harvest HCPs to reach a target of less than 100ppm at the end of process purification and clarification of the entire 2000L harvest. Incorporation of the Clarisolve® filters also had a positive impact on downstream steps including reducing the number of filters needed, the volume of water needed to wash the filter and the dilution of the material after the wash. With a reduced dilution, the capture step following the filtration required less time.

BioReliance® End-to-End Solutions is an adaptable CDMO partner for small biotechs and start-ups needing to develop and commercialize biologics. We do this by balancing speed, risk and cost through custom solutions, by leveraging our bioprocessing technologies and process development expertise, and by allowing our clients to transfer their process and knowledge to their end point at any step of their drug development. To learn more, please visit [EMDMillipore.com/adaptive-CDMO](https://EMDMillipore.com/adaptive-CDMO)

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

© 2019 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, the vibrant M, Clarisolve and BioReliance are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available on publicly accessible resource

MS\_DS4726EN Ver. 0.0 2019-25157 10/2019

